NYSE · HAE

Haemonetics Corporation

Healthcare · Medical - Instruments & Supplies

$90.80

Up+$0.42 (+0.46%)

Updated Aug 15, 2026, 6:47 PM

SID Score

6.6/10

Composite research score

Smart Money

58/100

Neutral

Market cap: 4.12B
P/E ratio: 23.87
Dividend yield: 0.00%
52-week range: $47.32 – $92.25
Volume: 533.28K
Avg. volume: 976.76K

Price performance

HAE price history

1M range · 21 trading sessions · Daily adjusted prices

Last close: $90.80
Period change: +16.62%
Period low: $77.40
Period high: $91.34

Daily close

View OHLC price history

HAE OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Aug 14, 2026	$90.61	$91.49	$89.82	$90.80	533.28K
Aug 13, 2026	$91.63	$92.25	$89.91	$90.38	811.85K
Aug 12, 2026	$86.38	$91.39	$86.14	$91.34	822.99K
Aug 11, 2026	$86.79	$88.88	$86.1029	$87.22	745.39K
Aug 10, 2026	$87.39	$87.97	$85.9701	$86.61	571.13K
Aug 7, 2026	$85.55	$87.87	$84.88	$87.84	657.08K
Aug 6, 2026	$85.77	$88.00	$80.83	$85.02	1.28M
Aug 5, 2026	$86.02	$86.94	$83.32	$83.60	1.14M
Aug 4, 2026	$86.06	$87.08	$85.32	$85.38	1.27M
Aug 3, 2026	$86.25	$88.585	$86.03	$86.79	1.06M
Jul 31, 2026	$84.26	$85.61	$82.75	$85.54	789.61K
Jul 30, 2026	$84.58	$84.97	$83.475	$84.82	555.2K
Jul 29, 2026	$81.99	$85.71	$81.7199	$85.42	893.44K
Jul 28, 2026	$81.14	$83.24	$80.37	$82.54	803.46K
Jul 27, 2026	$79.35	$80.72	$79.35	$79.91	803.18K
Jul 24, 2026	$78.32	$79.41	$77.27	$78.78	462.74K
Jul 23, 2026	$77.65	$78.345	$74.95	$77.40	598.29K
Jul 22, 2026	$78.17	$78.38	$76.22	$78.03	363.41K
Jul 21, 2026	$77.41	$78.15	$76.935	$78.07	371.76K
Jul 20, 2026	$77.81	$79.57	$77.59	$78.17	577.72K
Jul 17, 2026	$77.36	$78.7199	$77.11	$77.86	493.01K

Latest HAE news

The latest Smart Investors Daily articles mentioning HAE.

analystJun 26, 2026

BTIG Reiterates Buy Rating on Haemonetics Corporation (HAE)

sec filingMar 3, 2026

HAEMONETICS CORP (HAE) Reports Material Event to SEC

earningsFeb 6, 2026

Haemonetics (HAE) Beats Q3 Earnings Estimates by $0.05

Latest HAE news

The latest Smart Investors Daily articles mentioning HAE.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

HAE research

Overview

Company profile and research snapshot.

Company profile

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: $82.00
Implied upside: —
Analysts: —

HAE recent ratings
Date	Firm	Rating	Target
Aug 7, 2026	JP Morgan	Neutral	—
Aug 7, 2026	Citigroup	Neutral	—
Aug 6, 2026	BTIG	Buy	—
Jul 15, 2026	Mizuho	Outperform	—
Jun 26, 2026	BTIG	Buy	—

Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation

Benzinga · Feb 23, 2026

Haemonetics Receives FDA Clearance For NexSys PCS Plasma Collection System

Yahoo · Feb 20, 2026

Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET.

Yahoo · Feb 18, 2026